Because deletion of Atrx sensitizes sarcoma cells to oncolytic herpes virus and radiation therapy, tumors with loss-of-function mutations in ATRX may be particularly sensitive to the combination of oncolytic herpesvirus with radiation therapy. This evidence concerns the gene ATRX and sarcoma.